PLAINTIFF'S
EXHIBIT
DUP-965

MOUNT SINAI SCHOOL OF MEDICINE FACULTY

[illegible]

GUEST FACULTY

[illegible]

Course Registration Form
SCIENTIFIC BASIS FOR EVALUATION
OF ASBESTOS-ASSOCIATED DISEASE
The Mount Sinai Medical Center
December 13-16, 1982

NAME

ADDRESS

Street

City State Zip

TELEPHONE

Area Code and Number

SPECIALTY

I desire admission to:
[illegible]

FEE [illegible] (Source material, function, refreshments included)

Check should be made payable to: THE PAGE AND WILLIAM BLACK POST-GRADUATE SCHOOL OF MEDICINE and forwarded with this form.

Members of Associated Alumni of the Mount Sinai Hospital and Mount Sinai School of Medicine will be given a 20% reduction on all tuitions of the Post-Graduate School unless specifically noted otherwise.

REFUND POLICY: 100 will be refunded to cover administrative expenses if refund is requested in order to meet the balance, we must receive written notice of withdrawal one week before the course begins.

SIGNATURE

SEND TO: DIRECTOR, THE PAGE AND WILLIAM BLACK POST-GRADUATE SCHOOL OF MEDICINE, MOUNT SINAI SCHOOL OF MEDICINE, ONE GUSTAVE L. LEVY PLACE, NEW YORK, NEW YORK 10029. Telephone (212) [illegible].

Course Material

All participants will be given the following materials:

A detailed course outline of approximately 150 pages.

An annotated bibliography containing 2,000 important references to biological effects of asbestos.

"Disability Compensation for Asbestos-Associated Disease in the United States" prepared by Irving J. Selikoff, M.D. and sub-leagues for the Department of Labor, June, 1982.

Professor Paul Mahony's Work Paper, No. 37 "The Scenario Consequences of Asbestos Disease," through the courtesy of the School of Management of Yale University.

Information consultations by appointment, without fee, for extended review of particular points will be arranged, although these may include multiple participants.

As an organization accredited for continuing medical education, The Page and William Black Post-Graduate School of Medicine of the Mount Sinai School of Medicine (CUNY) certifies that this continuing medical education offering meets the criteria, basis for how, for Category I credit of the Physician's Recognition Award of the American Medical Association.

The Page and William Black Post-Graduate School of Medicine of the Mount Sinai School of Medicine reserves the right to cancel a course.

THE PAGE AND WILLIAM BLACK
POST-GRADUATE SCHOOL OF MEDICINE

THE MOUNT SINAI MEDICAL CENTER
One Gustave L. Levy Place
Fifth Avenue and 100th Street
Lee C. Stern Auditorium
The Annenberg Building
New York, New York 10029

SPECIAL COURSE

SCIENTIFIC BASIS for EVALUATION OF ASBESTOS-ASSOCIATED DISEASE

Irving J. Selikoff, M.D.
Course Director

Ruth Lilis, M.D., William J. Nicholson, Ph.D.,
Arthur M. Langer, Ph.D.,
Arthur L. Frank, M.D., Ph.D.,
Yasunosuke Suzuki, M.D., Albert Miller, M.D.
E. Cuyler Hammond, Sc.D.
Co-Directors

ENVIRONMENTAL SCIENCES LABORATORY
DEPARTMENT OF COMMUNITY MEDICINE
MOUNT SINAI SCHOOL OF MEDICINE

DECEMBER 13-16, 1982

MOUNT SINAI HOSPITAL OF NEW YORK CITY
THE PAGE AND WILLIAM BLACK POST-GRADUATE SCHOOL OF MEDICINE
MOUNT SINAI SCHOOL OF MEDICINE (CUNY)
One Gustave L. Levy Place, New York, N.Y. 10029

Scientific Basis for Evaluation of Asbestos-Associated Disease
December 13-16, 1982

DUP 0537061

PLAINT POST

DU 038097

The Environmental Sciences Laboratory, Department of Community Medicine
and The Page and William Black Post-Graduate School of Medicine
of the Mount Sinai School of Medicine (CUNY)

Announce a Special Course

SCIENTIFIC BASIS for EVALUATION OF ASBESTOS-ASSOCIATED DISEASE

December 13-16, 1982

Registration: Monday, December 13, 1982 at 8:00 AM.—Fee $650, (including luncheons.
Morning Sessions 9:00 AM to 12:30 PM. Lunch: 12:30 PM to 1:30 PM.
Afternoon Sessions: 1:30 PM to 5:30 PM

Under the Direction of IRVING J. SELIKOFF, M.D.

Course Co-Directors: Ruth Lilis, M.D., Ph.D., William J. Nicholson, Ph.D.,
Arthur M. Langer, Ph.D., Arthur L. Frank, M.D., Ph.D., Tsourouaure Suzuki, M.D.,
Albert Miller, M.D., E. Cuyler Hammond, Sc.D.

With Guest Faculty and Mount Sinai School of Medicine Faculty

Much scientific information is now available concerning asbestos-associated disease. An overriding consequent is long clinical latency: cancer and asbestosis now being seen are surviving legacies of past exposures. In the same light, current inadequately controlled exposures will be followed by disease in the future. There are thus two tasks: to attend to results of past mistakes and to take those steps necessary to prevent future problems. Both approaches are necessary.

Equally important are measures to ameliorate disease among those already exposed—early diagnosis, effective treatment where possible and preventive management where feasible.

Data will be reviewed to assist concerning human health consequences of asbestos exposure, with particular reference to those perspectives and concepts which underlie evaluation of the wide spectrum of public health responses needed for control of asbestos disease problems ranging from low-level environmental exposures and occupational disease, to management of asbestos cancers and asbestosis, to disability compensation of those injured by asbestos, and to considerations of how surveillance of asbestos-exposed populations might be undertaken.

There will be a mock trial to review important medical-legal issues.

Participation will be limited to 400 individuals. Informal consultations, by appointment, may be arranged.

MONDAY MORNING

1. Asbestos-associated diseases—1982. I. J. Selikoff, M.D., W. J. Nicholson, Ph.D., H. Seidman, MBA, J. G. Bekesi, Ph.D.
   Spectrum of non-neoplastic and neoplastic diseases. Asbestosis (lung and pleura), lung cancer, mesotheliomas of pleura, peritoneum, pericardium, cancer of oesophagus, stomach, colon-rectum, cancer of oropharynx, larynx, kidney.
   Diseases without incidence of "statistical significance" or of uncertain relevance. Rheumatoid arthritis (Caplan's syndrome), neoplasms of brain, pancreas.
   Occupational and non-occupational exposure populations at risk, 1982.
   Statistical approaches to risk assessments; disease projections 1982-2030.
2. Asbestos, asbestos fibers, asbestos bodies. A.M. Langer, Ph.D., A.N. Rohl, Ph.D.
   Mineralogy. Chrysotile, crocidolite, amosite, anthophyllite, tremolite.
   Asbestiform minerals, other than commercial asbestos. Metal and non-metal mining. Quarrying.
   Environmental exposure. Turkey, Bulgaria, Finland, Greece, endemic asbestos-induced disease. Recent observations in the United States.
   Commercial and industrial complexity.
   Tissue burdens in asbestos disease. Advantages and limitations of tissue analysis.

MONDAY AFTERNOON

3. Pathology of asbestos disease.
   Asbestosis. J. Kleinerman, M.D. Interstitial pulmonary fibrosis. Early parenchymal lesions. Conversion with ultrastructural changes. Mixed dust pneumoconiosis. Emphysema. Small airways changes. Pleural changes: pleural effusions, fibrosis, plaques, calcification.
   Lung cancer. V. Sunesel, M.D., A. Ehrlich, M.D. Commentary with lung cancer not related to asbestos. Cell types, variation, accuracy of diagnosis. Relation to extent of asbestosis.
   Mesotheliomas. V. Sunesel, J. Chang. Specificity of histological diagnosis. Extended studies, including special histochemistry and electron microscopy. Differential diagnosis; accuracy, including consideration of carcinoma and non-neoplastic pleural disease.
4. Basic principles of asbestos disease. I. J. Selikoff, M.D., R. Lilis, M.D., W. J. Nicholson, Ph.D., A. S. Tolnstein, M.D., A. Frank, M.D., Ph.D., J. G. Bekesi, Ph.D.
   Definitions.
   Cellular responses, fibrosis, neoplasia.
   Latency, induction period.
   Dose-response relation in asbestos disease.
   Multiple factor interaction considerations.
   Pleural disease: comparison with other pneumoconioses.
   Pulmonary function changes.
   Radiologic standards for assessing pulmonary function, impairment/disability.
   Reference standards for X-ray observations.
   Impairment and disability.

TUESDAY MORNING

5. Tobacco smoking. I. J. Selikoff, M.D., E. C. Hammond, Sc.D., H. Seidman, MBA
   Importance of vigorous smoking as incidence of asbestos disease.
   Smoking-associated asbestos disease. Disease not associated.
   Comparative contribution of influence of vigorous smoking.
   Smoking and fibrosis. Current observations.
   Pipe and cigar smoking.
   Effects of cessation of smoking.
6. Pleural disease with asbestos exposure. R. Lilis, M.D., R. Besson, M.D., E. C. Hammond, M.D., S. Levin, M.D., Y. Suzuki, M.D., A. Miller, M.D., I. J. Selikoff, M.D., H. Seidman, MBA
   Definitions. Review of Pathology.
   Radiological appearances.
   Respiratory function changes.
   Evidence of exposure vs. risk of disease.
   Prognosis significance.

TUESDAY AFTERNOON

7. Radiological changes in asbestosis. I. J. Selikoff, M.D., C. S. Rubin, M.D., R. Lilis, M.D., A. Fraenkel, M.D., J. Rabinowitz, M.D., A. S. Tolnstein, M.D.
   Parenchymal abnormalities. Reticular infiltration. Linear changes. "Honeycomb appearance." Upper lobe predilection. Combined pleuroparenchymal observations. Hyalinization. Large opacities. Consolidation, rounding, cysts.

WEDNESDAY MORNING

9. Family contact disease. W. J. Nicholson, Ph.D., H. Seidman, MBA
   Radiological abnormalities among household contacts of asbestos workers, asbestos factory workers.
   Mortality experience of family members of asbestos-exposed workers. Mesothelioma. Lung cancer.
   Projections associated contact disease, 1982-2000.
10. Environmental asbestos disease. W. J. Nicholson, Ph.D., A.M. Langer, Ph.D., A. L. Frank, M.D., Ph.D.
    Natural sources of asbestos and water pollution.
    Office buildings, public spaces.
    Neighborhood concern.
    Community problems.
    Asbestos lung burden in environmental circumstances.
    Quantitative estimates of disease risk from environmental exposure.
    The upward process of asbestos.

WEDNESDAY AFTERNOON

11. Impairment and disability in asbestosis. C.S. Rubin, M.D., R. Lilis, M.D., A. Miller, M.D., A. S. Tolnstein, M.D., I. J. Selikoff, M.D.
    Pulmonary function testing and interpretation.
    Observation and evaluation.
    Correlations and discrepancies among clinical findings/pulmonary function test performance/radiological changes.
    Importance of vigorous smoking.
    Estimates of disability for medical-legal purposes.
    Impairment and disability associated with pleural changes.
    Small airways disease.
12. Medical surveillance of asbestos-exposed persons. I. J. Selikoff, M.D., R. Lilis, M.D., E. C. Hammond, M.D., J. G. Bekesi, Ph.D.
    Details of an effective medical surveillance program.
    Potential for altering disease risk.
    Selection of pulmonary function tests.
    Results of Insulators survey, 1963; findings in 2,000 workers.
    Potential influence of surveillance on disease projections 1982-2030, disability and mortality.
    Implementation and administration.
13. Asbestos exposure: past, present, future. W. J. Nicholson, Ph.D., A. N. Rohl, Ph.D., A. S. Fleischer, Ph.D., R. Lilis, M.D.
    Utilization of asbestos minerals.
    Evaluation of materials.
    Assessment sources of future asbestos exposure.
    Problems of maintenance and repair.
    School exposure.
    Waste disposal.
    Asbestos contamination of public water supplies.

THURSDAY

14. A mock trial will be presented. It will address current issues and will discuss legal appreciation sometimes not appreciated in medical thinking but which are central to current trial issues.

DU 038098

DU 038098